73 related articles for article (PubMed ID: 30430324)
1. Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status.
McClintock TR; von Landenberg N; Cole AP; Lipsitz SR; Gild P; Sun M; Fletcher SA; Roghmann F; Menon M; Nguyen PL; Noldus J; Choueiri TK; Kibel AS; Trinh QD
Ann Surg Oncol; 2019 Jan; 26(1):297-305. PubMed ID: 30430324
[TBL] [Abstract][Full Text] [Related]
2. Surgery with or Without Darolutamide in High-risk and/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol.
Calleris G; Filleron T; Kesch C; Roubaud G; Pradère B; Cabarrou B; Malavaud B; Roupret M; Mourey L; Ploussard G
Eur Urol Oncol; 2024 Jun; 7(3):494-500. PubMed ID: 37806843
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone.
Akitake N; Shiota M; Obata H; Takeuchi A; Kashiwagi E; Imada K; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Prostate Int; 2018 Sep; 6(3):104-109. PubMed ID: 30140660
[TBL] [Abstract][Full Text] [Related]
4. Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer.
McKay RR; Choueiri TK; Taplin ME
Drugs; 2013 Sep; 73(13):1417-30. PubMed ID: 23943203
[TBL] [Abstract][Full Text] [Related]
5. The role of androgen deprivation therapy prior to radical prostatectomy in high-risk prostate cancer: a systematic review.
Arroyo-Rojas Y; Rodriguez-Sanchez L; Colandrea G; Otaola Arca H; Lanz C; Barret E; Sanchez-Salas R; Macek P; Cathelineau X
Minerva Urol Nephrol; 2024 Apr; 76(2):141-147. PubMed ID: 38742549
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular and Thromboembolic Events in Patients With Localized Prostate Cancer Receiving Intensified Neoadjuvant Androgen Deprivation: A Systematic Review and Meta-Analysis.
Felício de Campos E; Xavier CB; Queiroz MM; Firmino Lima Júnior N; Ilario EN; Coelho RF; Nahas WC; Bastos DA; Fontes Jardim DL
Clin Genitourin Cancer; 2024 Apr; 22(3):102088. PubMed ID: 38718699
[TBL] [Abstract][Full Text] [Related]
7. Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.
Wang X; Harshman LC; Xie W; Nakabayashi M; Qu F; Pomerantz MM; Lee GS; Kantoff PW
J Clin Oncol; 2016 Feb; 34(4):352-9. PubMed ID: 26668348
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Therapy in High-Risk Prostate Cancer.
Ashrafi AN; Yip W; Aron M
Indian J Urol; 2020; 36(4):251-261. PubMed ID: 33376260
[TBL] [Abstract][Full Text] [Related]
9. Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality.
Tilki D; Chen MH; Wu J; Huland H; Graefen M; Braccioforte M; Moran BJ; D'Amico AV
JAMA Oncol; 2019 Feb; 5(2):213-220. PubMed ID: 30452521
[TBL] [Abstract][Full Text] [Related]
10. Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer.
Borno HT; Lichtensztajn DY; Gomez SL; Palmer NR; Ryan CJ
Cancer; 2019 Feb; 125(3):453-462. PubMed ID: 30444526
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer: A meta-analysis of randomized controlled trials.
Gong P; Liu H; Liu X; Zhou G; Liu M; Yang X; Xiong W; Wang Q; Ma J; Ren Z; He M; Zhang X
Medicine (Baltimore); 2018 Nov; 97(46):e13204. PubMed ID: 30431595
[TBL] [Abstract][Full Text] [Related]
12. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
Yang DD; Mahal BA; Muralidhar V; Martin NE; Orio PF; Mouw KW; King MT; Choueiri TK; Trinh QD; Hoffman KE; Spratt DE; Feng FY; Nguyen PL
Eur Urol; 2019 Jan; 75(1):35-41. PubMed ID: 30554605
[TBL] [Abstract][Full Text] [Related]
13. Local failure is a dominant mode of recurrence in locally advanced and clinical node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy.
Hayman J; Hole KH; Seierstad T; Perin J; DeWeese TL; Tran PT; Lilleby W
Urol Oncol; 2019 Apr; 37(4):289.e19-289.e26. PubMed ID: 30446451
[TBL] [Abstract][Full Text] [Related]
14. Treatment of the primary tumor in metastatic prostate cancer.
Yuan Y; Kishan AU; Nickols NG
World J Urol; 2019 Dec; 37(12):2597-2606. PubMed ID: 30456709
[TBL] [Abstract][Full Text] [Related]
15. Comparison of testis cancer-specific survival: an analysis of national cancer registry data from the USA, UK and Germany.
Withington J; Cole AP; Meyer CP; Seisen T; Schmid M; Lipsitz SR; Sweeney CJ; Dasgupta P; Trinh QD
BJU Int; 2019 Mar; 123(3):385-387. PubMed ID: 30536825
[No Abstract] [Full Text] [Related]
16. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
17. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
18. Chemohormonal therapy for metastatic hormone-sensitive prostate cancer: An Asian perspective.
Teoh JY; Ng CF; Poon DM
Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():5-8. PubMed ID: 30489034
[TBL] [Abstract][Full Text] [Related]
19. Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer.
Bottke D; Bartkowiak D; Siegmann A; Thamm R; Böhmer D; Budach V; Wiegel T
Prostate Cancer Prostatic Dis; 2019 May; 22(2):344-349. PubMed ID: 30487644
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Approaches Prior To Radical Prostatectomy.
Ryan ST; Patel DN; Parsons JK; McKay RR
Cancer J; 2020; 26(1):2-12. PubMed ID: 31977379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
